Cytoreductive Radical Prostatectomy in Oligometastatic Prostate Cancer and the Role of the Robotic Platform: A Narrative Review.
- 1Department of Urology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Universidad Complutense de Madrid, 28040 Madrid, Spain.
- 2Department of Urology, Unidade Local de Saúde de São José, 1150-199 Lisbon, Portugal.
- 3Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-003, Brazil.
Abstract
Background: Oligometastatic prostate cancer (OMPC) comprises biologically and clinically distinct states with a limited number of detectable metastases. Improved systemic therapy and prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) have intensified interest in treating the primary tumor. Methods: In this narrative review we searched PubMed/MEDLINE from inception to 1 July 2026, reviewed current guidelines, and searched ClinicalTrials.gov, the ISRCTN registry and the EU Clinical Trials Register for ongoing surgical studies, prioritizing randomized trials, prospective studies, PSMA PET-staged cohorts, systematic reviews, guidelines, and studies of perioperative, functional and patient-reported outcomes. Results: Registry and institutional data generated the hypothesis that cytoreductive prostatectomy improves outcomes but are vulnerable to selection bias; prospective and PSMA PET-staged cohorts established feasibility. The phase II trial by Dai and colleagues supported radical treatment of the primary tumor but combined surgery and radiotherapy. RAMPP provided the first prostatectomy-specific randomized signal, with lower 5-year cancer-specific mortality after radical prostatectomy plus best systemic therapy than after systemic therapy alone (13% versus 23%; hazard ratio 0.39, 95% confidence interval 0.16-0.98), but accrual ended early, clinical progression was similar, overall survival was not significantly improved, systemic therapy predated contemporary intensification, and major surgery-related complications occurred in 14%. A randomized phase II trial with a predominantly surgical local-therapy arm found no progression-free or overall survival benefit, so randomized evidence is mixed. All randomized evidence concerns radical prostatectomy or local treatment irrespective of surgical approach; no trial has tested a robot-specific oncologic effect. Guidelines recommend prostate radiotherapy for selected low-volume de novo metastatic disease and restrict surgery to clinical trials. Conclusions: Cytoreductive prostatectomy, delivered mostly as robot-assisted radical prostatectomy (RARP), is feasible and may improve local control while providing complete pathology, but it remains investigational; the robotic approach is the surgical platform, not a modality with distinct oncologic efficacy. Appropriate use requires expert-center surgery, modern staging, guideline-concordant systemic therapy, multidisciplinary selection, transparent counseling and, preferably, trial participation. Future trials must establish whether prostatectomy adds meaningful benefit beyond modern systemic therapy, prostate radiotherapy and metastasis-directed treatment, while measuring morbidity, continence and quality of life.
Related
- Comparative outcomes of radical prostatectomy, radiotherapy, and radiotherapy plus androgen deprivation therapy for high-risk and very high-risk prostate cancer: a narrative review
- Gallium-68 (68Ga)-Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Initial Staging of High-Risk Prostatic Adenocarcinoma: Reclassification to Oligometastatic Disease and Change in Treatment Intent
- Feasibility and early outcomes of salvage robot-assisted radical prostatectomy after focal therapy failure for localized prostate cancer
- Acute Lymphopenia and Recovery With Prophylactic Pelvic Nodal Radiotherapy in Oligometastatic Prostate Cancer: Interim Results From the Prospective PROLONG2 Cohort.
- Surgical Team Composition and Outcomes After Radical Prostatectomy for Prostate Cancer.
BibTeX
@article{rivas2026cytoreductive,
title = {{Cytoreductive Radical Prostatectomy in Oligometastatic Prostate Cancer and the Role of the Robotic Platform: A Narrative Review.}},
author = {Juan Gomez Rivas and Pedro Gabriel Silva and Helena Margot Flôres Soares da Silva and Luís Severo and Luís Campos Pinheiro and Isabel Galante Romo and Enrique Redondo-González and Claudia González-Santander and Jesús Moreno Sierra},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18193207},
url = {https://europepmc.org/article/MED/42882901},
note = {CC BY},
}
RIS
TY - JOUR
TI - Cytoreductive Radical Prostatectomy in Oligometastatic Prostate Cancer and the Role of the Robotic Platform: A Narrative Review.
AU - Juan Gomez Rivas
AU - Pedro Gabriel Silva
AU - Helena Margot Flôres Soares da Silva
AU - Luís Severo
AU - Luís Campos Pinheiro
AU - Isabel Galante Romo
AU - Enrique Redondo-González
AU - Claudia González-Santander
AU - Jesús Moreno Sierra
PY - 2026
DA - 2026/10/04
JO - Cancers
DO - 10.3390/cancers18193207
UR - https://europepmc.org/article/MED/42882901
AB - Background: Oligometastatic prostate cancer (OMPC) comprises biologically and clinically distinct states with a limited number of detectable metastases. Improved systemic therapy and prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) have intensified interest in treating the primary tumor. Methods: In this narrative review we searched PubMed/MEDLINE from inception to 1 July 2026, reviewed current guidelines, and searched ClinicalTrials.gov, the ISRCTN registry and the EU Clinical Trials Register for ongoing surgical studies, prioritizing randomized trials, prospective studies, PSMA PET-staged cohorts, systematic reviews, guidelines, and studies of perioperative, functional and patient-reported outcomes. Results: Registry and institutional data generated the hypothesis that cytoreductive prostatectomy improves outcomes but are vulnerable to selection bias; prospective and PSMA PET-staged cohorts established feasibility. The phase II trial by Dai and colleagues supported radical treatment of the primary tumor but combined surgery and radiotherapy. RAMPP provided the first prostatectomy-specific randomized signal, with lower 5-year cancer-specific mortality after radical prostatectomy plus best systemic therapy than after systemic therapy alone (13% versus 23%; hazard ratio 0.39, 95% confidence interval 0.16-0.98), but accrual ended early, clinical progression was similar, overall survival was not significantly improved, systemic therapy predated contemporary intensification, and major surgery-related complications occurred in 14%. A randomized phase II trial with a predominantly surgical local-therapy arm found no progression-free or overall survival benefit, so randomized evidence is mixed. All randomized evidence concerns radical prostatectomy or local treatment irrespective of surgical approach; no trial has tested a robot-specific oncologic effect. Guidelines recommend prostate radiotherapy for selected low-volume de novo metastatic disease and restrict surgery to clinical trials. Conclusions: Cytoreductive prostatectomy, delivered mostly as robot-assisted radical prostatectomy (RARP), is feasible and may improve local control while providing complete pathology, but it remains investigational; the robotic approach is the surgical platform, not a modality with distinct oncologic efficacy. Appropriate use requires expert-center surgery, modern staging, guideline-concordant systemic therapy, multidisciplinary selection, transparent counseling and, preferably, trial participation. Future trials must establish whether prostatectomy adds meaningful benefit beyond modern systemic therapy, prostate radiotherapy and metastasis-directed treatment, while measuring morbidity, continence and quality of life.
SN - 2072-6694
ER -